Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Rehabilitation for Patients With Pulmonary Arterial Hypertension
Patients suffering from pulmonary arterial hypertension (PAH) frequently remain symptomatic despite medical therapy. Symptoms include breathlessness, poor exercise capacity and reduced quality of life.
- Trial name
- NCT00544726
- Testing
- Physical training, No training
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Rabin Medical Center
Pulmonary Arterial Hypertension
Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities
The purpose of this study is to compare the bioavailability of a single 1mg dose of treprostinil diethanolamine sustained release (SR) tablets manufactured by two independent facilities.
- Trial name
- NCT01165476
- Testing
- Treprostinil diethanolamine
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
This study is collecting post-marketing information on the safety and effectiveness of Ventavis under the routine clinical practice for patients with PAH
- Trial name
- NCT02825160
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- Japan
- Volunteers
- 282 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension
The goal of this clinical trial is to learn if an exercise programme started shortly after diagnosis improves the fitness and mental wellbeing of patients with pulmonary hypertenion over and above medication alone.
- Trial name
- NCT07366879
- Testing
- Home-based, remotely delivered, supervised Exercise programme
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Golden Jubilee National Hospital
Right Heart Failure, Pulmonary Hypertension
Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure
Secondary hyperaldosteronism and the non-osmotic release of arginine vasopressin (AVP) are the major factors in sodium and water retention in pulmonary arterial hypertension with right ventricular failure.
- Trial name
- NCT00811486
- Testing
- Spironolactone and conivaptan
- Where
- United States
- Sponsor
- University of Colorado, Denver
Pulmonary Arterial Hypertension
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which included a dose titration period. An additional transition period occurred for those patients who elected to enroll into the open-label…
- Trial name
- NCT02279160
- Testing
- APD811
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 61 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Xenon MRI Pulm Hypertension
The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with…
- Trial name
- Jupiter PH (NCT04991454)
- Testing
- 129Xe Hyperpolarized
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bastiaan Driehuys
Hypertension, Pulmonary
Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
The objective of this post-marketing surveillance study is to evaluate the incidence of adverse events in Japanese subjects with pulmonary arterial hypertension treated with ambrisentan basd on prescribing information under the…
- Trial name
- NCT01406327
- Testing
- Ambrisentan
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension
The objective of this randomized control trial is to gain clinical insight on the use of pulmonary artery denervation (PADN) for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- PADN-CFDA (NCT03282266)
- Testing
- PADN
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Arterial Hypertension
(-)-Epicatechin and Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease that results in severe activity limitation and death. There are few treatments for PAH and the available medications are expensive, difficult to administer and have…
- Trial name
- NCT01880866
- Testing
- (-)-Epicatechin
- Where
- United States
- Sponsor
- University of California, San Francisco
Pulmonary Arterial Hypertension
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension
Previously characterised PAH patients, including idiopathic, heritable and other forms of group 1 PAH with and without BMPR2 mutation which have already been analysed and are regularly seen in the Center for Pulmonary…
- Trial name
- AMIA (NCT04086537)
- Testing
- hepcidin levels and BMPR2 expression
- Where
- Germany
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise
The study aim is to monitor, during exercise tests carried out in various conditions, the alveolar dead space, by means of continuous transcutaneous measurement of Pt CO2, which would be used as a surrogate for arterial PaCO2.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Chronic Heart Failure, Pulmonary Arterial Hypertension
- Trial name
- TEASE (NCT03718780)
- Testing
- simultaneous determination of PaCO2 and PtCO2, Hyperventilation test, Exercise test
- Where
- 4 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Metropole Savoie
Myeloproliferative Disorder, Myelodysplastic Syndromes
Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases
Myelodysplastic and myeloproliferative Disease represent conditions with increased risk for pulmonary hypertension. However, the exact prevalence of pulmonary hypertension in these conditions is not known.
- Conditions
- Myeloproliferative Disorder, Myelodysplastic Syndromes, Pulmonary Hypertension
- Trial name
- NCT00909467
- Testing
- echocardiography, right heart catheterisation
- Where
- Austria
- Volunteers
- 86 people
- Sponsor
- Medical University of Graz
Congenital Heart Disease, Cardiomyopathy
Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and Pediatric Patients With Congenital Heart Disease
The goal of this observational study, drug-free, cross-sectional, single-center is to describe the incidence and characteristics of the clinical course and any short- and medium-term complications of patients with congenital…
- Conditions
- Congenital Heart Disease, Cardiomyopathy, Pulmonary Arterial Hypertension, SARS CoV-2 Infection
- Trial name
- NCT06784687
- Where
- Italy
- Volunteers
- 2,376 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Severe Pulmonary Arterial Hypertension
Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan
To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.
- Trial name
- NCT02042014
- Testing
- QTI571
- Where
- 3 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Novel Index (PIMR) in PAH
The chief regulator of resistance in pulmonary arterial hypertension (PAH) is the small arteries. In the heart, the invasive measurement of the resistance of the small arteries has been shownto be safe, easy, reliable, and…
- Trial name
- NCT05812976
- Testing
- Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, Los Angeles
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension
This methodological study aims to develop and validate a questionnaire named for the Assessment of Patient Knowledge in Pulmonary Arterial Hypertension.
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension
- Trial name
- SAVOIR (NCT07120789)
- Testing
- Application of Patient Knowledge Questionnaire on Pulmonary Hypertension
- Where
- Brazil
- Volunteers
- 215 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension
Neuromuscular Electrical Stimulation in Pulmonary Arterial Hypertension
This study aimed to investigate the effects of neuromuscular electrical stimulation on peripheral muscles and other physical and psychosocial variables in patients with pulmonary arterial hypertension.
- Trial name
- NCT03612115
- Testing
- Neuromuscular electrical stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- Dokuz Eylul University
Pulmonary Arterial Hypertension (PAH)
Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes
This is a multicenter retrospective cohort study on pulmonary arterial hypertension. It is expected to collect data from no less than 5,000 patients to compare the long-term overall survival of patients with and without diabetes…
- Trial name
- NCT07082933
- Testing
- Standard medical treatment
- Volunteers
- 5,000 people
- Sponsor
- Xijing Hospital
Pulmonary Arterial Hypertension
Goal Oriented Strategy to Preserve Ejection Fraction Trial
In this prospective long term feasibility study we examine whether a goal oriented therapeutic strategy that is able to preserve right ventricular function will result in improved clinical outcome in patients with pulmonary…
- Trial name
- GOSPEL (NCT03236818)
- Testing
- ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Amsterdam UMC, location VUmc